589 related articles for article (PubMed ID: 17287473)
1. Taking TRIPS to India--Novartis, patent law, and access to medicines.
Mueller JM
N Engl J Med; 2007 Feb; 356(6):541-3. PubMed ID: 17287473
[No Abstract] [Full Text] [Related]
2. Is India ready to lead the battle for fair access to medicines?
Lancet Oncology
Lancet Oncol; 2013 May; 14(6):437. PubMed ID: 23639313
[No Abstract] [Full Text] [Related]
3. [Novartis should discontinue its patent case in India!].
PehrOlov P
Lakartidningen; 2007 Feb 14-20; 104(7):524. PubMed ID: 17375688
[No Abstract] [Full Text] [Related]
4. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
't Hoen E
Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
[No Abstract] [Full Text] [Related]
5. Engineered in India--patent law 2.0.
Kapczynski A
N Engl J Med; 2013 Aug; 369(6):497-9. PubMed ID: 23862973
[No Abstract] [Full Text] [Related]
6. Final hearings begin in epic legal battle over Novartis drug in India.
Mudur G
BMJ; 2012 Sep; 345():e6257. PubMed ID: 22991008
[No Abstract] [Full Text] [Related]
7. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
[TBL] [Abstract][Full Text] [Related]
8. Amendments to the Canadian Patent Act to address drug access: is help on the way?
Penner MD; Narayanan P
Food Drug Law J; 2005; 60(3):459-70. PubMed ID: 16304751
[No Abstract] [Full Text] [Related]
9. The GO License: only part of the solution.
Batson A; Milstien JB
Health Aff (Millwood); 2008; 27(1):140-2. PubMed ID: 18180489
[TBL] [Abstract][Full Text] [Related]
10. Reforming Canada's Access to Medicines Regime.
Elliott R
CMAJ; 2007 Jul; 177(3):270-1. PubMed ID: 17664453
[No Abstract] [Full Text] [Related]
11. TRIPS, pharmaceuticals, developing countries, and the Doha "solution".
Sykes AO
Chic J Int Law; 2002; 3(1):47-68. PubMed ID: 15709299
[No Abstract] [Full Text] [Related]
12. Access to essential drugs, human rights and global justice.
Shalev C
Monash Bioeth Rev; 2004 Jan; 23(1):S56-74. PubMed ID: 15835024
[No Abstract] [Full Text] [Related]
13. Patent necessity: intellectual property dilemmas in the biotech domain and treatment equity for developing countries.
Spectar JM
Houst J Int Law; 2002; 24(2):227-78. PubMed ID: 16189914
[No Abstract] [Full Text] [Related]
14. Drugs are scarce as mix of programs aims to ease access.
Brower V
J Natl Cancer Inst; 2009 Oct; 101(19):1304-6. PubMed ID: 19755680
[No Abstract] [Full Text] [Related]
15. Tripping over patents: AIDS, access to treatment and the manufacturing of scarcity.
Berger JM
Conn J Int Law; 2002; 17(2):157-248. PubMed ID: 12688292
[No Abstract] [Full Text] [Related]
16. Drug resistance, patent resistance: Indian pharmaceuticals and the impact of a new patent regime.
Halliburton M
Glob Public Health; 2009; 4(6):515-27. PubMed ID: 19548158
[TBL] [Abstract][Full Text] [Related]
17. Intellectual property. Challenges to India's pharmaceutical patent laws.
Sampat BN; Shadlen KC; Amin TM
Science; 2012 Jul; 337(6093):414-5. PubMed ID: 22767892
[No Abstract] [Full Text] [Related]
18. How do public health safeguards in Indian patent law affect pharmaceutical patenting in practice?
Sampat BN; Amin T
J Health Polit Policy Law; 2013 Aug; 38(4):735-55. PubMed ID: 23645877
[TBL] [Abstract][Full Text] [Related]
19. Impact of India's new patents law 2005: a physician's perspective.
Lele RD
J Assoc Physicians India; 2005 Aug; 53():671-5. PubMed ID: 16398073
[No Abstract] [Full Text] [Related]
20. Thailand and the compulsory licensing of efavirenz.
Steinbrook R
N Engl J Med; 2007 Feb; 356(6):544-6. PubMed ID: 17287474
[No Abstract] [Full Text] [Related]
[Next] [New Search]
